Center for Neuropsychiatric Schizophrenia Research (CNSR) and Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Denmark.
Faculty of health and Medical Science, Department of Clinical Medicine, University of Copenhagen, Denmark.
Int J Neuropsychopharmacol. 2022 Aug 16;25(8):613-618. doi: 10.1093/ijnp/pyac029.
Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52 patients with first-episode psychoses (24 females, age 23.1 ± 5.2 years) and 57 matched HCs (20 females, age 22.7 ± 4.3 years) before and after 6 weeks where patients received aripiprazole monotherapy (mean dose 10.4 mg ± 4.8 mg). At baseline, patients displayed lower levels of vitamin C (57.4 ± 25.9 µM) than controls (72.7 ± 21.4 µM) (t = 3.4, P = .001). Baseline symptoms and vitamin C levels were not correlated. Higher baseline vitamin C levels were associated with more improvement in negative symptoms (n = 39, R2 = 0.20, F = 8.2, P = .007), but not with age, sex, or p-aripiprazole. Because negative symptoms are generally considered challenging to alleviate, a potential adjunctive effect of vitamin C on treatment response should be tested in future randomized clinical trials.
患者的维生素 C 水平较低观察到在精神分裂症和精神病患者,和维生素 C 可能会影响多巴胺能系统。同样,抗精神病药物调节纹状体多巴胺 D2 受体。我们测量了维生素 C 水平在 52 例首发精神病患者(24 名女性,年龄 23.1±5.2 岁)和 57 例匹配的健康对照者(20 名女性,年龄 22.7±4.3 岁)在 6 周后,患者接受阿立哌唑单药治疗(平均剂量 10.4mg±4.8mg)。在基线时,患者的维生素 C 水平(57.4±25.9µM)低于对照组(72.7±21.4µM)(t=3.4,P=0.001)。基线症状和维生素 C 水平没有相关性。较高的基线维生素 C 水平与阴性症状的改善更相关(n=39,R2=0.20,F=8.2,P=0.007),但与年龄、性别或 p-阿立哌唑无关。因为阴性症状通常被认为是难以缓解的,维生素 C 对治疗反应的潜在辅助作用应该在未来的随机临床试验中进行测试。